# Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection

> **NCT02722837** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 119 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** SOF/VEL

## Key facts

- **NCT ID:** NCT02722837
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-04
- **Primary completion:** 2017-06-26
- **Final completion:** 2017-09-13
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02722837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02722837, "Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02722837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*